AEterna Zentaris - Stock Price History | AEZS

Historical daily share price chart and data for AEterna Zentaris since 2021 adjusted for splits. The latest closing stock price for AEterna Zentaris as of October 15, 2021 is 0.60.
  • The all-time high AEterna Zentaris stock closing price was 6826.63 on June 16, 2000.
  • The AEterna Zentaris 52-week high stock price is 3.62, which is 503.3% above the current share price.
  • The AEterna Zentaris 52-week low stock price is 0.29, which is 51.7% below the current share price.
  • The average AEterna Zentaris stock price for the last 52 weeks is 0.80.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
AEterna Zentaris Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 0.6570 0.8815 1.4399 0.2987 0.4255 -53.24%
2019 2.6081 3.0300 5.4300 0.7716 0.9100 -69.05%
2018 2.0058 2.3700 3.8700 1.1900 2.9400 24.58%
2017 2.1091 3.5000 3.6500 0.8388 2.3600 -34.44%
2016 3.5338 4.4000 4.9400 2.6700 3.6000 -19.64%
2015 29.7027 60.0100 84.2000 4.0000 4.4800 -92.53%
2014 113.0131 144.0000 150.0000 52.0000 60.0000 -56.52%
2013 181.3772 253.0000 323.0000 103.0000 138.0000 -42.02%
2012 478.8337 947.8104 1289.7421 187.0000 238.0000 -74.24%
2011 1117.9890 1043.7912 1547.6905 857.8284 923.8152 -10.47%
2010 711.7805 493.1014 1253.7493 473.9052 1031.7936 113.16%
2009 718.8250 287.9424 1697.6605 275.9448 484.0432 64.67%
2008 633.9757 929.8140 1079.7840 239.9520 293.9412 -68.18%
2007 1816.5400 2369.5261 2615.4769 875.8848 923.8152 -61.98%
2006 3501.0021 3119.3761 4439.1122 2429.5141 2429.5141 -20.59%
2005 3016.3917 3785.2430 3785.2430 2489.5021 3059.3881 -18.53%
2004 3482.4702 2045.5909 4889.0222 1985.6029 3755.2490 85.21%
2003 2468.8872 2243.5513 4241.1518 1469.7061 2027.5945 -9.38%
2002 2553.6321 3455.3089 4031.1938 1157.7684 2237.5525 -37.63%
2001 3589.6530 4427.1146 5098.9802 2381.5237 3587.2825 -18.97%
2000 5153.0430 6376.7247 6826.6347 3185.3629 4427.1146 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.073B $0.004B
AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00